sonidegib: Clinical Trials

17 trials of sonidegib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 5 terminated, 1 active not recruiting, 1 recruiting. 17 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 217Completed 8, Terminated 5, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1
Phase 13Completed 2, Terminated 1

Follow sonidegib: new trials by email Literature Review of sonidegib trials Research Report on sonidegib

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
Irinotecan, Sonidegib, Sorafenib - Hepatocellular Carcinoma
Phase 2RecruitingUniversity of Florida122024-12-022026-07-14
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
Sonidegib, Cisplatin, Lomustine - Medulloblastoma
Phase 2TerminatedEuropean Organisation for Research and Treatment of Cancer - EORTC202022-11-112025-10-23
Anti-PD1-antibody and Pulsed HHI for Advanced BCC
Cemiplimab Injection [Libtayo] - Basal Cell Carcinoma
Phase 2UnknownReinhard Dummer202021-02-182024-07-30
Tailored Sonidegib Schedule After Complete Response in BCC
Sonidegib - Locally Advanced Basal Cell Carcinoma
Phase 2Active not recruitingGruppo Oncologico del Nord-Ovest212021-01-122026-06-01
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
Sonidegib, Imiquimod, Surgery - Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified
Phase 2CompletedMelanoma Institute Australia162019-07-232025-12-16
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Buparlisib, Sonidegib - Carcinoma, Basal Cell, Recurrent Skin Cancer
Phase 2TerminatedAnne Chang102015-02-012019-01-29
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
LDE225, Bortezomib - Multiple Myeloma
Phase 2TerminatedSCRI Development Innovations, LLC72015-01-012017-02-16
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
Erismodegib, Placebo - Breast Neoplasms
Phase 2WithdrawnWashington University School of Medicine2014-04-012015-04-27
LDE225 for Patients With PTCH1 or SMO Mutated Tumors
LDE225 - PTCH1 or SMO Activated Solid and Hematologic Tumors
Phase 2TerminatedNovartis Pharmaceuticals102014-02-012016-05-02
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Laboratory Biomarker Analysis, Lenalidomide, Sonidegib - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Phase 2CompletedMayo Clinic282014-01-172021-12-03
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
LDE225, INC424 - Primary Myelofibrosis, Thrombocytosis
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals502013-05-082020-04-15
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
LDE225, TMZ - Medulloblastoma
Phase 2CompletedNovartis Pharmaceuticals222013-05-062017-08-11
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
LDE225 - Acute Leukemias
Phase 2CompletedNovartis Pharmaceuticals702013-05-012016-08-30
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
LDE225-600mg, Gemcitabine, nab-paclitaxel - Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins232011-12-272020-01-22
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
LDE225 - Basal Cell Carcinoma
Phase 2CompletedNovartis Pharmaceuticals2302011-06-292019-08-28
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
LDE225, Placebo - Basal Cell Carcinoma, Gorlin Syndrome
Phase 2CompletedNovartis Pharmaceuticals102011-04-012015-10-19
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
LDE225 - Medulloblastoma, Rhabdomyosarcoma
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals762011-02-012017-03-20

Conditions studied

Carcinoma, Basal Cell (5)  ·  Basal Cell Nevus Syndrome (3)  ·  Medulloblastoma (3)  ·  Recurrence (3)  ·  Skin Neoplasms (3)  ·  Multiple Myeloma (2)  ·  Astrocytoma (1)  ·  Blood Coagulation Disorders (1)  ·  Blood Platelet Disorders (1)  ·  Bone Marrow Diseases (1)  ·  Breast Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Hepatocellular (1)  ·  Colonic Neoplasms (1)  ·  Endometrial Neoplasms (1)

Sponsors

Novartis Pharmaceuticals (7)  ·  Anne Chang (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  Gruppo Oncologico del Nord-Ovest (1)  ·  Mayo Clinic (1)  ·  Melanoma Institute Australia (1)  ·  Reinhard Dummer (1)  ·  SCRI Development Innovations, LLC (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  University of Florida (1)  ·  Washington University School of Medicine (1)

Countries

United States (10)  ·  Australia (7)  ·  Canada (6)  ·  Germany (6)  ·  Italy (6)  ·  France (5)  ·  Spain (5)  ·  United Kingdom (5)  ·  Belgium (4)  ·  Netherlands (4)  ·  Switzerland (4)  ·  Austria (3)  ·  Hungary (2)  ·  Brazil (1)  ·  Denmark (1)

Top investigators

Ali Zarrinpar, MD, PhD (1)  ·  Ana De Jesus-Acosta, MD (1)  ·  Anne Lynn Chang, MD (1)  ·  Cynthia Ma, M.D., Ph.D. (1)  ·  Francis Buadi (1)  ·  Jesus G. Berdeja, M.D. (1)  ·  Paolo Bossi, MD (1)  ·  Pascale Guitera, MD PhD (1)  ·  Peter Hau (1)  ·  Rebecca Aft, M.D., Ph.D. (1)  ·  Reinhard Dummer, Prof. (1)

Results publications

PMID 25981810, PMID 28846163, PMID 29175429, PMID 32634234, PMID 34669179, PMID 34798846

NIH funding

P30CA015083 (1)